Fekal mikrobiotatransplantasjon ved behandling av immunsjekkpunkthemmer-indusert diaré eller kolitt hos pasienter med genitourinær kreft
Fekal mikrobiotatransplantasjon (FMT) for immunsjekkpunkthemmer-indusert diaré/kolitt hos pasienter med genitourinær kreft
This trial studies how well fecal microbiota transplantation works in treating diarrhea or colitis (inflammation of the intestines) that is caused by certain types of medications (called immune-checkpoint inhibitors) in patients with genitourinary cancer. Fecal microbiota transplantation may effectively reduce the incidence of immune checkpoint inhibitor-induced diarrhea/colitis.
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Detaljert beskrivelse
PRIMARY OBJECTIVES:
- To assess the safety and tolerability of fecal microbiota transplantation (FMT).
- To assess the efficacy of FMT for clinical remission/response of immune-related diarrhea/colitis.
SECONDARY OBJECTIVES:
- To measure the recurrence rate after achieving clinical remission/response of immune-related diarrhea/colitis.
EXPLORATORY OBJECTIVES:
- To assess the efficacy of FMT to achieve endoscopic remission of immune-related diarrhea/colitis.
- To assess the efficacy of FMT to achieve histological remission of immune-related diarrhea/colitis.
- To assess the efficacy of FMT on recurrence of immune-related diarrhea/colitis after resumption of immune checkpoint inhibitors (ICPI).
- To assess immunological, molecular and microbiome changes in tissue/blood/stool.
To study the efficacy and/ or benefit of PuraStat gel in the healing of mucosal ulcers and its hemostatic effect on bleeding lesions
OUTLINE:
Patients receive loperamide orally (PO). After 4 hours, patients undergo FMT via colonoscopy over 15-30 minutes.
After completion of study treatment, patients are followed up at 2, 4, and 8 weeks, and then at 3 months.
Studietype
Studietype
Registrering (Antatt)
Registrering
Fase
Fase
- Fase 1
Kontakter og plasseringer
Studiekontakt
Studiekontakt
- Navn: Yinghong Wang
- Telefonnummer: 281-221-9138
- E-post: ywang59@mdanderson.org
Studiesteder
-
-
Texas
-
Houston, Texas, Forente stater, 77030
- Rekruttering
- M D Anderson Cancer Center
-
Hovedetterforsker:
- Yinghong Wang
-
Ta kontakt med:
- Yinghong Wang
- Telefonnummer: 713-792-7672
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Diagnosis of any type of genitourinary (kidney, bladder and prostate), melanoma, non-melanoma skin cancer, lung, head & neck, sarcoma/lymphoma, gastrointestinal system (luminal GI, hepatobiliary, pancreas), gynecology system (ovarian, uterine, cervical), and breast malignancies
- Treatment with any ICPI agent(s)
- Participants with new onset of ≥ grade 2 ICPI-induced diarrhea and/or colitis symptoms based on the Common Terminology Criteria for Adverse Events (CTCAE) version 5 within 45 days prior to date of FMT treatment without involvement of non- GI toxicity
- Participants with a history of steroid use before FMT can be allowed if last dose was > 30 days prior to FMT treatment or treatment duration was for <7 days beyond one week prior to FMT treatment
- Participants with a history of immunosuppressant (Infliximab, Vedolizumab etc) use before FMT can be allowed if last dose was administered ≥ 3 months prior to FMT treatment when used for the treatment of conditions other than for ICI- induced GI toxicities (e.g., Infliximab is used in the treatment of Crohn's disease, rheumatoid arthritis, plaque psoriasis, and Vedolizumab is used in treating ulcerative colitis)
- No concern for active concomitant GI infection at the time of initiation of protocol therapy as confirmed by stool tests or as per the treating physician based on clinical presentation
- Patient has been cleared for enrollment by Infectious Diseases consultant or treating physician if positive infection workup or screening tests (e.g., lifelong positive T-spot due to BCG inoculation, chronic colonization) prior to initiation of protocol therapy and/ or imaging (e.g. CXR, CT CAP etc) confirms the absence of active infections (e.g. TB) within 60 days prior to initiation of protocol therapy
- Ability to understand and willingness to sign an informed consent form
- Life expectancy > 6 months
Exclusion Criteria
- Age younger than 18 years
- Participants with persistent GI infection confirmed with positive stool test(s) despite completing 5 days of antibiotics prior to initiation of protocol therapy
- History of inflammatory bowel disease, and/or radiation enteritis or colitis with active disease status at the time of study treatment initiation
- Pregnant and breastfeeding women
- Women who have positive urine or serum pregnancy test or refuse to do pregnancy test unless last menstrual cycle was > 1 year prior to consent and/ or clear documentation states that participant is peri- or post-menopausal or there has been recent supporting objective evidence of 'no pregnancy' status (e.g. blood or imaging) within 30 days prior to date of study treatment
- Immunosuppressive treatment at onset of ICPI-induced diarrhea/colitis
- Any medical conditions (e.g. severe heart failure, brain hemorrhage, septic shock, etc.) that are high risk for colonoscopy procedure by the assessment of the study PI or Co-PIs.
- Participants who develop concurrent non-GI toxicity at the time of study treatment
- Donors at risk for monkeypox infection and/ or exposure as determined by a questionnaire
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Eksperimentell: Treatment (loperamide, colonoscopy, FMT)
Patients receive loperamide PO. After 4 hours, patients undergo FMT via colonoscopy over 15-30 minutes. |
Undergo FMT via colonoscopy
Andre navn:
Given PO |
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence of fecal microbiota transplantation (FMT)-related adverse events
Tidsramme: Up to 3 months post-FMT
|
Assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 5. All events are recorded with grade and attribution to FMT. |
Up to 3 months post-FMT
|
|
Clinical response/remission of immune-related diarrhea/colitis
Tidsramme: At 2 weeks post-FMT
|
Clinical remission of immune related events defined as improvement of symptoms of grade 1 or lower within 2 weeks post-FMT. Clinical partial response of immune related diarrhea/colitis defined as improvement of diarrhea/colitis to a lower grade than the initial presentation but not meeting criteria of clinical remission at 2 week post-FMT time point. |
At 2 weeks post-FMT
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Recurrent immune-related diarrhea/colitis within 3 months post-FMT after initially achieving clinical remission/response
Tidsramme: Up to 3 months post-FMT
|
Recurrent immune-related diarrhea colitis events occurring post-FMT are recorded throughout the follow-up period. |
Up to 3 months post-FMT
|
Andre resultatmål
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Endoscopic remission (Mayo Clinic sub-score 0-1) of immune-related diarrhea/colitis
Tidsramme: At 4 weeks and 8 weeks post-FMT
|
Endoscopic remission is defined as Mayo Clinic endoscopic subscore 0 or 1 (absence of ulcers, with or without mild erythema, friability and decreased vascular pattern). |
At 4 weeks and 8 weeks post-FMT
|
|
Histological remission (resolution of active inflammation) of immune-related diarrhea/colitis
Tidsramme: At 8 weeks post-FMT
|
Histological remission is defined resolution of active inflammation on biopsy sample. |
At 8 weeks post-FMT
|
|
Recurrent immune-related diarrhea/colitis following FMT and immune checkpoint inhibitors (ICPI) resumption within 6 months of ICPI resumption
Tidsramme: Up to 6 months after restarting ICPI
|
Recurrent immune-related diarrhea colitis events occurring post-FMT will be recorded throughout the follow-up period. |
Up to 6 months after restarting ICPI
|
|
Measure immunological measures (including levels of cytokines (IL-6, 17, TNF, etc.) in tissue/blood/stool samples
Tidsramme: Up to 3 months
|
Blood, stool, and colon tissues will be collected from at each scheduled time point. Markers of interest for immunological and biological profiles include levels of cytokines (IL-6, 17, TNF, etc). Special attention will focus on Bacteroidetes, Akkermansia, and Blautia. |
Up to 3 months
|
|
Frequencies of immune cells (CD4/8 T cells, regulatory T cells [Treg], macrophages, etc.) in tissue/blood/stool samples
Tidsramme: Up to 3 months
|
Blood, stool, and colon tissues will be collected from at each scheduled time point. Markers of interest for immunological and biological profiles include frequencies of immune cells (CD4/8 T cells, Treg, macrophages, etc). Special attention will focus on Bacteroidetes, Akkermansia, and Blautia. |
Up to 3 months
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Samarbeidspartnere
Samarbeidspartnere
Etterforskere
Etterforskere
- Hovedetterforsker: Yinghong Wang, M.D. Anderson Cancer Center
Publikasjoner og nyttige lenker
Hjelpsomme linker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Studiestart
Primær fullføring (Antatt)
Primær fullføring
Studiet fullført (Antatt)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Urogenitale sykdommer
- Kjønnssykdommer
- Sykdommer i det endokrine systemet
- Neoplasmer etter nettsted
- Neoplasmer
- Mannlige urogenitale sykdommer
- Kvinnelige urogenitale sykdommer
- Kvinnelige urogenitale sykdommer og graviditetskomplikasjoner
- Tegn og symptomer, fordøyelseskanal
- Tarmsykdommer
- Sykdommer i luftveiene
- Neoplasmer etter histologisk type
- Sykdommer i fordøyelsessystemet
- Gastrointestinale sykdommer
- Livmorsykdommer
- Kjønnssykdommer, kvinner
- Lungesykdommer
- Neoplasmer i endokrine kjertel
- Neoplasmer i luftveiene
- Thoracale neoplasmer
- Kolonsykdommer
- Sykdommer i eggstokkene
- Adnexal sykdommer
- Genitale neoplasmer, kvinnelige
- Gonadal lidelser
- Hudsykdommer
- Gastroenteritt
- Bryst sykdommer
- Livmor livmorhalssykdommer
- Nevroektodermale svulster
- Neoplasmer, kjønnsceller og embryonale
- Neoplasmer, nervevev
- Nevroendokrine svulster
- Nevi og melanomer
- Neoplasmer i huden
- Patologiske tilstander, tegn og symptomer
- Hud- og bindevevssykdommer
- Tegn og symptomer
- Lungeneoplasmer
- Neoplasmer i eggstokkene
- Kolitt
- Brystneoplasmer
- Uterine cervikale neoplasmer
- Melanom
- Urogenitale neoplasmer
- Uterine neoplasmer
- Diaré
- Heterocykliske forbindelser, 1-ring
- Heterocykliske forbindelser
- Terapeutikk
- Piperidines
- Biologisk terapi
- Loperamid
- Fekal mikrobiota -transplantasjon
Andre studie-ID-numre
Andre studie-ID-numre
- 2018-0663
- 2018-0663 (Annen identifikator: M D Anderson Cancer Center)
- NCI-2019-02660 (Registeridentifikator: CTRP (Clinical Trial Reporting Program))
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .